| Literature DB >> 32757065 |
Abdullah F Alghannam1,2, Iain Templeman3, Joel E Thomas3, Dawid Jedrzejewski3, Samuel Griffiths3, Joseph Lemon3, Thomas Byers3, Sue Reeves4, Javier T Gonzalez3, Dylan Thompson3, James Bilzon3, Kostas Tsintzas5, James A Betts3.
Abstract
PURPOSE: To examine the influence of post-exercise protein feeding upon the adaptive response to endurance exercise training.Entities:
Keywords: Amino acids; Post-exercise nutrition; Recovery; Running; Sucrose
Mesh:
Substances:
Year: 2020 PMID: 32757065 PMCID: PMC7502056 DOI: 10.1007/s00421-020-04450-1
Source DB: PubMed Journal: Eur J Appl Physiol ISSN: 1439-6319 Impact factor: 3.078
Participant characteristics, including physiological parameters at baseline and follow-up
| All participants ( | CHO-P group ( | CHO group ( | ||||
|---|---|---|---|---|---|---|
| Baseline | Follow-up | Baseline | Follow-up | Baseline | Follow-up | |
| Age (years) | 20 ± 2 | – | 20 ± 2 | – | 20 ± 2 | – |
| Speed at 70% | 10.2 ± 1.0 | 10.7 ± 0.9 | 10.0 ± 1.0 | 10.6 ± 0.9 | 10.4 ± 0.9 | 10.9 ± 0.9 |
| Speed at 75% | 11.0 ± 1.0 | 11.6 ± 1.0 | 10.8 ± 1.1 | 11.4 ± 1.0 | 11.2 ± 1.0 | 11.8 ± 0.9 |
| Height (cm) | 179 ± 10 | – | 179 ± 10 | – | 179 ± 10 | – |
| Body mass (kg) | 76.3 ± 12 | 75.4 ± 10 | 77.7 ± 13 | 76.0 ± 11 | 73.9 ± 9 | 74.0 ± 8 |
| Body fat (%) | 16.3 ± 4.5 | 15.9 ± 3.6 | 15.8 ± 5.2 | 15.4 ± 3.9 | 17.0 ± 3.8 | 16.4 ± 3.4 |
| Body mass index (kg m2) | 23.8 ± 2.8 | 23.6 ± 2.3 | 24.3 ± 3.4 | 23.8 ± 2.7 | 23.1 ± 2.0 | 23.1 ± 1.7 |
| Resting heart rate (beats min−1) | 61 ± 7 | 56 ± 9* | 63 ± 6 | 57 ± 8* | 59 ± 7 | 54 ± 10* |
| Maximum heart rate (beats min−1) | 203 ± 10 | 197 ± 9* | 200 ± 12 | 195 ± 10* | 206 ± 7 | 199 ± 7* |
| Resting metabolic rate (kJ min−1) | 7721 ± 259 | 7733 ± 225 | 7686 ± 322 | 7849 ± 238 | 7757 ± 301 | 7607 ± 301 |
| Urine osmolality (mOsm kg−1) | 519 ± 347 | 592 ± 281 | 523 ± 349 | 584 ± 291 | 516 ± 359 | 600 ± 282 |
Values are mean ± SD
*Significant time effect from baseline to follow-up (p < 0.05)
Fig. 1Participant recruitment and flow throughout the protocol. CHO carbohydrate group, CHO-P carbohydrate–protein group
Fig. 2Schematic representation of the experimental protocol
Fig. 3Maximal oxygen uptake ()in CHO (n = 12; red coloured) and CHO-P (n = 13; blue coloured) groups. The open symbols represent individual scores; the horizontal and vertical lines represent mean ± standard deviation, respectively. a Absolute scores in L min−1 from baseline to follow-up in both groups; b change in in L min−1 from baseline to follow-up for both groups; c relative scores in mL kg−1 min−1 from baseline to follow-up in both groups; d change in in mL kg−1 min−1 from baseline to follow-up in both groups. *Significant main effect of time compared with baseline (p < 0.01). CHO carbohydrate, CHO-P carbohydrate–protein
Fig. 4Haematological parameters collected during the study in CHO (n = 12; red coloured) and CHO-P (n = 13; blue coloured) groups. The open symbols represent individual scores; the horizontal and vertical lines represent mean ± standard deviation, respectively. a Plasma albumin concentrations in g dL−1 from baseline to follow-up in both groups; b haemoglobin concentrations in g dL−1 from baseline to follow-up in both groups; c haematocrit ratio (%) from baseline to follow-up in both groups. *Significant main effect of time compared with baseline (p < 0.01). CHO carbohydrate, CHO-P carbohydrate–protein
Fig. 5Relative gene expression represented as fold change from baseline for several key genes related to mitochondrial biogenesis, muscle protein synthesis and carbohydrate/lipid metabolism. Values are mean ± SD. *p < 0.05 baseline vs follow-up. FOXO3 forkhead box O3, FABP3 fatty-acid binding protein 3, GLUT4 glucose transporter protein 4, HKII hexokinase II, PDK4 pyruvate dehydrogenase kinase 4, PPARg peroxisome proliferator-activated receptor gamma, PGC1-a peroxisome proliferator-activated receptor gamma coactivator 1-alpha, TFAM mitochondrial transcription factor A, P53 tumour suppressor p53, PPARd peroxisome proliferator-activated receptor delta, SIRT1 NAD-dependent deacetylase sirtuin-1, SIRT3 NAD-dependent deacetylase sirtuin-3, CS citrate synthase, p38MAPK P38 mitogen-activated protein kinase, ERK1 mitogen-activated protein kinase 3, ERK2 mitogen-activated protein kinase 1, AKT1 AKT serine/threonine kinase 1, EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1, mTOR mechanistic target of rapamycin, RPS6 ribosomal protein S6